Daiichi Sankyo

GPTKB entity

Statements (47)
Predicate Object
gptkbp:instanceOf gptkb:biotechnology
gptkbp:CEO gptkb:Sunao_Manabe
gptkbp:collaboratedWith gptkb:AstraZeneca
gptkb:Merck_&_Co.
gptkbp:divested Ranbaxy Laboratories (to Sun Pharma)
gptkbp:focus oncology
cardiovascular diseases
rare diseases
gptkbp:founded 2005
gptkbp:founder gptkb:Sankyo_Co.,_Ltd.
gptkb:Daiichi_Pharmaceutical
gptkbp:hasResearchCenter gptkb:Edogawa_R&D_Center
gptkb:Shinagawa_R&D_Center
gptkbp:headquartersLocation gptkb:Tokyo,_Japan
https://www.w3.org/2000/01/rdf-schema#label Daiichi Sankyo
gptkbp:industry pharmaceuticals
gptkbp:ISIN JP3475350009
gptkbp:listedOn gptkb:Nikkei_225
gptkbp:logo Daiichi Sankyo logo.svg
gptkbp:market gptkb:Europe
gptkb:Japan
gptkb:United_States
gptkbp:memberOf gptkb:Japan_Pharmaceutical_Manufacturers_Association
gptkbp:nativeName gptkb:第一三共株式会社
gptkbp:notable_drug Benicar (olmesartan, US)
Effient (prasugrel)
Enhertu (trastuzumab deruxtecan)
Lixiana (edoxaban)
Olmetec (olmesartan)
gptkbp:notableAcquisition gptkb:Ranbaxy_Laboratories
gptkbp:numberOfEmployees 16,000+
gptkbp:parentCompany gptkb:Daiichi_Sankyo_Group
gptkbp:products gptkb:Enhertu
gptkb:Edoxaban
gptkb:Nexium_(in_Japan)
gptkb:Olmesartan
gptkbp:rank Top 20 global pharmaceutical companies (by revenue)
gptkbp:revenue 1.2 trillion yen (FY2023)
gptkbp:romanization gptkb:Daiichi_Sankyō_Kabushiki-gaisha
gptkbp:servesArea worldwide
gptkbp:stockExchange gptkb:Tokyo_Stock_Exchange
gptkbp:stockSymbol 4568
gptkbp:subsidiary gptkb:Daiichi_Sankyo,_Inc._(USA)
gptkb:Daiichi_Sankyo_Europe_GmbH
gptkbp:website https://www.daiichisankyo.com/
gptkbp:bfsParent gptkb:NOVN
gptkbp:bfsLayer 5